Revvity RVTY · USD
Health Care · Life Sciences Tools & Services · US listing · 🇺🇸 United States
S&P 500
160.72
+3.62%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Revvity
From its filings with the US Securities and Exchange Commission
Revvity is based in Waltham, Massachusetts and is incorporated in Massachusetts. Its shares trade on NYSE under the ticker RVTY. It is a member of the S&P 500. The SEC classifies its business as laboratory analytical instruments. In the fiscal year to 28 December 2025, it reported revenue of $2.86bn and net income of $241.2m. At that date it held total assets of $12.17bn and shareholders' equity of $7.25bn.
We are a leading provider of health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.
Our headquarters are in Waltham, Massachusetts, and we market our products and services in more than 160 countries. As of December 28, 2025, we employed approximately 11,000 employees. Our common stock is listed on the New York Stock Exchange under the symbol “RVTY” and we are a component of the S&P 500 Index.
Our comprehensive portfolio of technologies helps life sciences researchers better understand diseases and develop treatments. We provide a broad suite of products, solutions, software and services that facilitate optimized workflows, increase productivity, and accelerate every stage of the drug discovery and development pipeline. Our offerings span the areas of cell, gene, and protein research, enabling scientists to work smarter, make research breakthroughs, and transform those breakthroughs into real-world outcomes. We partner with global pharmaceutical, biotech and contract research organizations, as well as academic and government institutions, to enable them to discover and develop better treatments and therapeutics to fight disease faster and more efficiently.
Quoted from its 10-K, filed 24 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 6 Jul 1965
- Employees
- 11,000
- Website
- perkinelmer.com ↗
- Head office
- 77 4TH AVENUE, WALTHAM, MA, 02451
- Incorporated in
- MA
- Classification
- Laboratory Analytical Instruments
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Alexandros MichasIndependent Non-Executive Chairman of the Board$449,995
- Dr. Prahlad SinghPresident, Chief Executive Officer, Director, since 2016$11.9m
- Mr. Maxwell KrakowiakChief Financial Officer, Senior Vice President$3.2m
- Mr. Joel GoldbergSenior Vice President - Administration, General Counsel, Secretary$3.4m
- Ms. Miriame VictorChief Commercial Officer, Senior Vice President$2.5m
- Mr. Tajinder VohraSenior Vice President - Global Operations$2.3m
- Mrs. Anita GonzalesVice President, Controller
- Dr. Peter BarrettIndependent Director$334,933
- Mr. Samuel ChapinIndependent Director$339,933
- Mr. Michael KlobucharIndependent Director$357,430
- Ms. Michelle Mcmurry-HeathIndependent Director$314,933
- Dr. Sophie VandebroekIndependent Director$362,430
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 88
- Environment
- 99
- Social
- 99
- Governance
- 67
- Direct emissions (scope 1)
- 2,121 t
- Energy emissions (scope 2)
- 29,581 t
- Women in the workforce
- 47%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Strong market presence: PerkinElmer Inc has established itself as a leading player in the scientific research and diagnostics sector, with a wide range of products and services.
- Technological expertise: The company possesses advanced technologies and innovative solutions, giving it a competitive edge in the market.
- Diversified product portfolio: PerkinElmer offers a diverse range of products across various segments, including life sciences, diagnostics, environmental testing, and food safety.
Weaknesses
- Dependence on key customers: PerkinElmer relies heavily on a few large customers for a significant portion of its revenue, which exposes it to potential risks if any of these customers reduce their business or switch to competitors.
- High research and development costs: Developing and maintaining advanced technologies requires substantial investments, which may strain the company's financial resources.
Opportunities
- Growing demand for diagnostics: The increasing prevalence of diseases and the need for early detection and accurate diagnosis provide a significant growth opportunity for PerkinElmer in the diagnostics market.
- Expansion in emerging markets: PerkinElmer can explore untapped markets in developing countries, leveraging its expertise to cater to the rising demand for scientific research and diagnostics solutions.
- Acquisitions and partnerships: Strategic acquisitions or partnerships with complementary companies can help PerkinElmer expand its product offerings and broaden its customer base.
Threats
- Intense competition: The scientific research and diagnostics market is highly competitive, with numerous established players and new entrants. PerkinElmer must continually innovate to stay ahead.
- Regulatory challenges: Changes in regulations and compliance requirements can affect the company's operations, potentially leading to increased costs or barriers to market entry.
- Economic downturns: Global economic uncertainties and recessions can impact the demand for PerkinElmer's products and services, as customers may reduce spending on research and diagnostics.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.